Deutsche Bank AG Buys 63,512 Shares of Prothena Co. plc (NASDAQ:PRTA)

Deutsche Bank AG lifted its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 195.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 95,970 shares of the biotechnology company's stock after purchasing an additional 63,512 shares during the quarter. Deutsche Bank AG owned 0.18% of Prothena worth $1,329,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PRTA. SG Americas Securities LLC increased its stake in Prothena by 167.0% in the fourth quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company's stock valued at $521,000 after acquiring an additional 23,525 shares during the last quarter. Barclays PLC increased its stake in Prothena by 10.6% in the fourth quarter. Barclays PLC now owns 105,338 shares of the biotechnology company's stock valued at $1,458,000 after acquiring an additional 10,116 shares during the last quarter. Duncan Williams Asset Management LLC increased its stake in Prothena by 41.9% in the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company's stock valued at $958,000 after acquiring an additional 20,450 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Prothena in the fourth quarter valued at approximately $1,117,000. Finally, Rhumbline Advisers boosted its position in Prothena by 1.8% in the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock valued at $930,000 after buying an additional 1,175 shares in the last quarter. 97.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PRTA has been the topic of a number of research analyst reports. Cantor Fitzgerald lowered shares of Prothena from an "overweight" rating to a "neutral" rating in a research report on Tuesday. HC Wainwright cut their target price on shares of Prothena from $30.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday. Royal Bank of Canada cut their price target on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a report on Friday, February 21st. JMP Securities dropped their target price on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a report on Tuesday. Finally, Bank of America restated an "underperform" rating on shares of Prothena in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $31.50.

Prothena Stock Performance

NASDAQ PRTA traded up $0.04 on Wednesday, hitting $4.62. The stock had a trading volume of 5,500,695 shares, compared to its average volume of 658,851. Prothena Co. plc has a 52-week low of $4.33 and a 52-week high of $25.42. The company has a market capitalization of $248.84 million, a price-to-earnings ratio of -1.98 and a beta of 0.11. The firm has a 50-day moving average of $9.38 and a 200-day moving average of $12.72.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same quarter in the prior year, the company earned ($1.34) earnings per share. The business's revenue for the quarter was up 5500.0% compared to the same quarter last year. As a group, research analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.